mannuronic acid has been researched along with Multiple Sclerosis in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 4 (80.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aghazadeh, Z; Beladi Moghadam, N; Manoucherinia, A; Mirshafiey, A; Movahedi, M; Najafi, S; Nikouei Moghaddam, MR; Noorbakhsh, SM; Pashaiefar, H; Saadat, P; Vali Mohammadi, A | 1 |
| Hosseini, M; Manouchehrinia, A; Matsuo, H; Mirshafiey, A; Moghadam, NB; Mohammadi, AV; Najafi, S; Noorbakhsh, SM; Saadat, P | 1 |
| Bananej, M; Mirshafiey, A; Moghadam, NB; Mokhtarian, F; Movahedi, M; Najafi, S; Nikouei Moghaddam, MR; Saadat, P | 1 |
| Aghazadeh, Z; Beladi Moghadam, N; Hosseini, M; Manoucherinia, A; Mirshafiey, A; Najafi, S; Pashaiefar, H; Saadat, P; Vali Mohammadi, A | 1 |
| Koh, CS; Matsuo, H; Mirshafiey, A; Miyoshi, S; Nakane, S; Rehm, BH | 1 |
1 trial(s) available for mannuronic acid and Multiple Sclerosis
| Article | Year |
|---|---|
A controlled, randomized phase II clinical trial for efficacy and safety evaluation of mannuronic acid in secondary progressive form of multiple sclerosis.
Topics: Adult; Hexuronic Acids; Humans; Interferon beta-1a; Interferon beta-1b; Middle Aged; Multiple Sclerosis; Multiple Sclerosis, Chronic Progressive; Young Adult | 2022 |
4 other study(ies) available for mannuronic acid and Multiple Sclerosis
| Article | Year |
|---|---|
The Effects of Mannuronic Acid on IL-1β, IL-17A, STAT1, and STAT3 Gene Expressions and TLR2 and TLR4 Molecules in Multiple Sclerosis.
Topics: Clinical Trials, Phase II as Topic; Gene Expression; Hexuronic Acids; Humans; Interleukin-17; Leukocytes, Mononuclear; Multiple Sclerosis; STAT1 Transcription Factor; STAT3 Transcription Factor; Toll-Like Receptor 2; Toll-Like Receptor 4 | 2022 |
Assessment of Biochemical Determinants in Multiple Sclerosis Patients Following the Oral Administration of β-D-Mannuronic Acid (M2000).
Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Hexuronic Acids; Humans; Multiple Sclerosis | 2021 |
Evaluation of the Effect of Mannuronic Acid as a Novel NSAID With Immunosuppressive Properties on Expression of SOCS1, SOCS3, SHIP1, and TRAF6 Genes and Serum Levels of IL-6 and TNF-α in Patients With Multiple Sclerosis.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Female; Gene Expression; Hexuronic Acids; Humans; Immunosuppressive Agents; Interleukin-6; Intracellular Signaling Peptides and Proteins; Male; Middle Aged; Multiple Sclerosis; Phosphatidylinositol-3,4,5-Trisphosphate 5-Phosphatases; Suppressor of Cytokine Signaling 1 Protein; Suppressor of Cytokine Signaling 3 Protein; Tumor Necrosis Factor-alpha | 2021 |
Novel immunosuppressive therapy by M2000 in experimental multiple sclerosis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Immunologic; Encephalomyelitis, Autoimmune, Experimental; Female; Hexuronic Acids; Immunization; Immunosuppressive Agents; Lymph Nodes; Multiple Sclerosis; Mycobacterium tuberculosis; Myelin Basic Protein; Rats; Rats, Inbred Lew; Time Factors | 2005 |